MNOV MediciNova Inc.

$11.78 -3.52%

87,564 Shares Traded
395,103 Average Volume (last 30 days)

as of March 22, 2018 EST IEX Real-Time Price

Short Pain Metrics

Approximate Amount of Money Shorts Have Made on the Day: $1.25 million
If Intiated on the First, Shorts Have Realized a Year to Date Return of:-78.48%
If Intiated One Month Ago, Shorts Have Realized a Return of:-6.99%
If Initiated Five Days ago, Shorts Have Realized a Return of:13.83%
Peer Potential Short Squeezes Near Real Time Screener
*Please note the actual returns of shorts could be different as they started from different points

Daily Indicators

Daily Short Pain Indicator [i] - Always Use Fundamentals on EverythingNeutral
200 Day Moving Average Indicator Bullish
50 Day Moving Average Indicator Bullish
52 Week High/Low Indicator Neutral

Short Stats

Short Percent to Float 7.4%
Short Interest2.9 million
Float39.19 million
Short Ratio5.94
Market Cap$483.62 million
Market Maker ActivityDaily Short Volume


Key events next week - healthcare (SeekingAlpha)
Merck KGaA's MS candidate evobrutinib successful in mid-stage study (SeekingAlpha)
Your Daily Pharma Scoop: Akebia Update, Rexahn Data, Concert Commences Enrollment (SeekingAlpha)
Your Daily Pharma Scoop: Adamas' Gocovri Key Value Driver, BioMarin Data, Regeneron Q4 Results (SeekingAlpha)
Premarket Losers as of 9:05 am (2/8/2018) (SeekingAlpha)
Midday Gainers / Losers (2/6/2018) (SeekingAlpha)
Premarket Gainers as of 9:05 am (02/06/2018) (SeekingAlpha)
Your Daily Pharma Scoop: MediciNova's MN-166, Amgen's Results, TG Therapeutics Data (SeekingAlpha)
Kicking Off Avisol's 'Theme Of The Month' Series With A Look At NASH And Intercept (SeekingAlpha)
MediNova's MN-166 reduced progression of MS by 26% in mid-stage study (SeekingAlpha)

Smart Money Sentiment

Institutional Ownership (Top 15 Funds) 13.2%

Earnings Stats

PE Ratio -42.07
Dividend Yield 0%
Peer EarningsEarnings Calendar


200 Day Moving Average $7
50 Day Moving Average $10.17
52 Week High $14.5
52 Week Low $4.4

Data provided for free by IEX. Questions? Read the FAQ